Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3369-3376

  Höltl, Lorenz ^a   Zelle Rieser, Claudia ^a   Gander, Hubert ^a   Papesh, Christine ^a   Ramoner, Reinhold ^a   Bartsch, Georg ^a   Rogatsch, Hermann ^b   Barsoum, Adel L ^c   Coggin, Joseph H ^c   Thurnher, Martin ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN; CYTOKINE; HEMOCYANIN; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; AUTOLOGOUS MONOCYTE DERIVED DENDRITIC CELL VACCINE; CANCER VACCINE; INTERLEUKIN 1BETA; LAMININ RECEPTOR; ONCOFETAL ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MONOCYTE; PATHOLOGY; TREATMENT OUTCOME; ALLERGIC REACTION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL LYSATE; CELL MATURATION; CLINICAL ARTICLE; DRUG TOLERABILITY; EVALUATION; FLU LIKE SYNDROME; FOLLOW UP; IMMUNE RESPONSE; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, RENAL CELL; CELL DIVISION; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; FEMALE; HEMOCYANIN; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; NEOPLASM METASTASIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036845714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Motzer, R. J., Bander, N. H., and Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med., 335: 865-875, 1996
2. Belldegrun, A., Muul, L. M., and Rosenberg, S. A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity. Cancer Res., 48: 206-214, 1988
3. Thurnher, M., Radmayr, C., Hobisch, A., Bock, G., Romani, N., Bartsch, G., and Klocker, H. Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int. J. Cancer, 62: 559-564, 1995
4. Thurnher, M., Radmayr, C., Ramoner, R., Ebner, S., Bock, G., Klocker, H., Romani, N., and Bartsch, G. Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer, 68: 1-7, 1996
5. Mulders, P., Figlin, R., deKernion, J. B., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W., and Belldegrun, A. Renal cell carcinoma: Recent progress and future directions. Cancer Res., 57: 5189-5195, 1997
6. Thurnher, M., Rieser, C., Holtl, L., Papesh, C., Ramoner, R., and Bartsch, G. Dendritic cell-based immunotherapy of renal cell carcinoma. Urol. Int., 61: 67-71, 1998
7. Jaffee, E. M., and Pardoll, D. M. Gene therapy: Its potential applications in the treatment of renal-cell carcinoma. Semin. Oncol., 22: 81-91, 1995
8. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshall, F. F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537-1546, 1997
9. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998
10. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994
11. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Down-regulation by cytokines and bacterial products. J. Exp. Med., 182: 389-400, 1995
12. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994
13. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996
14. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998
15. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Bartsch, G., and Thurnher, M, CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet, 352: 1358, 1998
16. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Herold, M., Klocker, H., Radmayr, C., Stenzl, A., Bartsch, G., and Thurnher, M. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen-pulsed dendritic cells. J. Urol., 161: 777-782, 1999
17. Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S., Schlom, J., Ryback, M. E., and Lyerly, H. K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 5: 1331-1338, 1999
18. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., Smits, B. J., Sopapan, P., Strang, G., Valone, F. H., and Vuk-Pavlovic, S. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res., 6: 2175-2182, 2000
19. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V., and Valone, F. H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol., 18: 3894-3903, 2000
20. Nishiyama, T., Tachibana, M., Horiguchi, Y., Nakamura, K., Ikeda, Y., Takesako, K., and Murai, M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res., 7: 23-31, 2001
21. Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., Fujie, T., Tanaka, F., Inoue, H., Takesako, K., Akiyoshi, T., and Mori, M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res., 7: 2277-2284, 2001
22. Shimizu, K., Thomas, E. K., Giedlin, M., and Mule, J. J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res., 61: 2618-2624, 2001
23. Schnurr, M., Galambos, P., Scholz, C., Then, F., Dauer, M., Endres, S., and Eigler, A. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res., 61: 6445-6450, 2001
24. Brossart, P., Stuhler, G., Flad, T., Stevanovic, S., Rammensee, H. G., Kanz, L., and Brugger, W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res., 58: 732-736, 1998
25. Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A., Rammensee, H. G., Kanz, L., and Brugger, W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood, 93: 4309-4317, 1999
26. 2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production. J. Exp. Med., 186: 1603-1608, 1997
27. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., and Enk, A. H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 27: 3135-3142, 1997
28. Rieser, C., Ramoner, R., Holtl, L., Rogatsch, H., Papesh, C., Stenzl, A., Bartsch, G., and Thurnher, M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int., 63: 151-159, 1999
29. Zelle-Rieser, C., Barsoum, A. L., Sallusto, F., Ramoner, R., Rohrer, J. W., Höltl, L., Bartsch, G., Coggin, J. J., and Thurnher, M. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. J. Urol., 165: 1705-1709, 2001
30. Coggin, J. H., Jr., Barsoum, A. L., and Rohrer, J. W. Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol. Today, 19: 405-408, 1998
31. Fong, L., Brockstedt, D., Benike, C., Wu, L., and Engleman, E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol., 166: 4254-4259, 2001
32. Morse, M. A., Coleman, R. E., Akabani, G., Niehaus, N., Coleman, D., and Lyerly, H. K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 59: 56-58, 1999
33. Iezzi, G., Scheidegger, D., and Lanzavecchia, A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J. Exp. Med., 193: 987-993, 2001
34. Steinbrink, K., Jonuleit, H., Muller, G., Schuler, G., Knop, J., and Enk, A. H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 93: 1634-1642, 1999
35. Mocellin, S., Wang, E., and Marincola, F. M. Cytokines and immune response in the tumor microenvironment. J. Immunother., 24: 392-407, 2001
36. Cella, M., Engering, A., Pinet, V., Pieters, J., and Lanzavecchia, A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (Lond.), 388: 782-787, 1997
37. Sallusto, F., and Lanzavecchia, A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev., 177: 134-140, 2000
38. Roncarolo, M. G., Levings, M. K., and Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med., 193: F5-F9, 2001
39. Thurnher, M., Zelle-Rieser, C., Ramoner, R., Bartsch, G., and Höltl, L. The disabled dendritic cell. FASEB J., 15: 1054-1061, 2001
40. Spanbroek, R., Hildner, M., Kohler, A., Muller, A., Zintl, F., Kuhn, H., Radmark, O., Samuelsson, B., and Habenicht, A. J. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc. Natl. Acad. Sci. USA, 98: 5152-5157, 2001
41. Robbiani, D. F., Finch, R. A., Jager, D., Muller, W. A., Sartorelli, A. C., and Randolph, G. J. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3β. ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell, 103: 757-768, 2000
42. Yamaoka, K. A., Claesson. H. E., and Rosen, A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J. Immunol., 143: 1996-2000, 1989
43. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med., 188: 2357-2368, 1998
44. Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., and Belardelli, F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med., 191: 1777-1788, 2000
45. Parlato, S., Santini, S. M., Lapenta, C., Di Pucchio, T., Logozzi, M., Spada, M., Giammarioli, A. M., Malorni, W., Fais, S., and Belardelli, F. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities. Blood, 98: 3022-3029, 2001